Jan 29 (Reuters) - Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a muscle wasting disorder, than its older drug Exondys 51. (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.1 USD | 0.00% | +0.25% | +57.74% |
Jun. 26 | Monetary policy is getting even more confusing | |
Jun. 26 | Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.74% | 14.38B | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+147.53% | 12.37B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta says its experimental Duchenne drug more effective than older medicine